Endomines production in Q4 was weaker than expected, but further gold price momentum continues to ca...
Xplora's monthly subscriptions update shows that the Xplora Kids subscriber base for Q4 2025 ended a...
Redeye lowers its forecasts and Base Case slightly, which, however, remains substantially above the ...
Redeye comments on the news that the TRANBERG Thermal Therapy System for focal laser ablation (FLA) ...
At SEB's Nordic Seminar, CFO Larsen highlighted how management spent 2025 broadly derisking the equi...
At SEB’s Nordic Seminar, Gofore's CEO emphasised that that the company is currently much better equi...
Redeye provides an update on Biovica following the Q2 2025/2026 report, which showed weaker-than-exp...
Redeye’s conviction in BI-1808 increases with the latest readout in platinum-resistant ovarian cance...
We expect Duell’s sales and adjusted EBITA to both decline y/y in Q1.
Redeye provides a brief comment on the unexpected announcement that Episurf Medical intends to acqui...
Redeye comments on SSH Communications Security's profit warning issued today, where the company lowe...
* '26e-'27e EBIT up 19-15% * Entering 2026 with a simpler structure * '26e-'27e EV/EBIT of 21x-8x Ca...
Redeye briefly comments on Alligator Bioscience announcing the outcome of its rights issue, with 64.
CapMan announced this morning the launch of fourth flagship fund in Natural Capital.
In a decision published today by the Swedish Competition Authority, we find that they have concluded...
Gofore acquires small German digital consulting company Esentri AG for EUR 10m, as a multiple broadl...
Redeye has changed lead analyst of Cheffelo and provides a preview ahead of the company’s Q4 report ...
Redeye's analyst comments the recent in a Research Note.
Redeye updates on Vitrolife after a site visit and a change of lead analyst.
Last Friday, Arise announced the acquisition of a 10 MW (22 GWh) wind farm in SE2, commissioned in 2...
